BROADCASTS.com

Chris Calhoun is the CEO of Paracrine Cell Therapy which has a different approach to regenerative medicine. This biologic approach uses an autologous cell therapy approach, taking a mixture of a patient's own cells, not just one cell type to address underlying pathologies through multiple mechanisms of action. Using a device that sits at the point of care, fat is extracted and the cells are processed and put back in the patient in about an hour.

Chris explains, "It's interesting that if you look at the evolution of most of the therapies out there today, drug therapies and so forth, they generally treat the symptoms, and they target one mechanism. We're taking a very different approach. We're looking at treating complex conditions and diseases where there are multiple underlying issues or conditions or pathologies, depending on how you want to look at it. We think that this sort of silver bullet approach doesn't necessarily work to address more complex diseases where you've got these multiple underlying conditions."

"Well, it's an emerging field, so I think there are various approaches. We're really the unique company out there that's focused on this heterogeneous or this mixed cell population approach to regenerative medicine via device. Probably the most important distinction ... well, there's two. One, I think the clinical benefits of this mixed cell population are becoming clear, and second is the economic aspect of it. We are not isolating these cells and growing them in a laboratory, and engineering them in any specific way that ultimately ends up costing orders of hundreds of thousands of dollars per treatment or sequence of treatments for a single patient."

#Paracrine #RegenerativeMedicine #CellTherapy #AutologousCellTherapy

Paracrine.com

Download the transcript here